Pharmacogenetics (DPYD / UGT1A1 only)
DPYD and/or UGT1A1 pharmacogenetic testing for drug response and efficacy (Germline DNA).
Pharmacogenetics (panel testing)
Pharmacogenetic panel testing of markers for drug response and efficacy (Germline DNA).
Ovarian, Breast, Prostate and Pancreatic Cancers (PARPi) [DNA, Germline]
BRCA1 and BRCA2 testing for Ovarian, Breast, prostate and pancreatic cancer (Germline DNA) in the context of PARP inhibitor prescription. This EQA is sponsored.
Ovarian and Prostate Cancer (PARPi) [Tissue, Somatic]
BRCA1, BRCA2 and HRR testing for Ovarian and Prostate cancer in the context of PARP inhibitor prescription (FFPE). This EQA is sponsored.
Breast Cancer (AKT Pathway Gene Testing) [Tissue]
PIK3CA, AKT1 and PTEN gene testing in breast cancer (FFPE)
Comprehensive Genomic Profiling (CGP)
Identification of different types of variants and genomic signatures by CGP in solid tumour (FFPE). This is a pilot EQA (genotyping only), places are limited, complete the form to express interest in participation (see participant information section).